chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The full body rashes started immediately after my second dose of the vaccine and then lasted more than 1 month and never went away on its own. So I sought medical treatment and used prescription Fluocinonide 0.05% Ointment for 2 weeks.  Finally the rashes went away at the end of  the 2-week treatment on Jun 20.   My mom also had rashes right after her second dose of Pfizer vaccine but her rashes were only on her scalp and her eyelids were extremely swollen. Our family dentist also told us she knows another woman who had rashes after Covid vaccine. I googled mRNA Covid vaccine rashes and found it typically start after the first dosage and resolves on its own without treatment, and then reappear with less severity after second dose. Moderna also cause 'Covid arm'. My mom's and my rashes are different from the typical Pfizer vaccine rashes.
This case was reported by a physician via call center representative and described the occurrence of swelling in a adult patient who received Shingrix for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced swelling, influenza-like symptoms and muscle pain. On an unknown date, the outcome of the swelling, influenza-like symptoms and muscle pain were unknown. It was unknown if the reporter considered the swelling, influenza-like symptoms and muscle pain to be related to Shingrix. Additional details were reported as follows: The age group was not reported but was selected as adult as per vaccine indication. The healthcare professional reported that the patient experienced problems of swelling, muscle aches and flu-like symptoms after Shingrix. The healthcare professional would not provide any additional information outside of what was reported above.
Adverse -Redness, swelling, soreness, numbness tingling of the fingers and hands. Treatment - Antibiotics.
Very cold after previous 3 doses; This spontaneous case was reported by a patient and describes the occurrence of NASOPHARYNGITIS (Very cold after previous 3 doses) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Flu vaccine (had them for the last 5 yrs with no affect.). Past adverse reactions to the above products included No adverse event with Flu vaccine.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced NASOPHARYNGITIS (Very cold after previous 3 doses). At the time of the report, NASOPHARYNGITIS (Very cold after previous 3 doses) outcome was unknown.            No concomitant medications were reported. No treatment medications were reported.   This case was linked to MOD-2022-654912 (Patient Link).   Reporter did not allow further contact
Ringing in ears is much louder after getting the second vaccine shot. It has not gone away after 5 days
(Chicken pox) varicella rash present on trunk.  Less than 60 spots. No current exposure to varicella that mom is aware of rash began 06/28/2001
Patient presented to the ED and was subsequently hospitalized within 6 weeks of receiving booster dose. The visit was for unstable angina.
BREAKTHROUGH COVID INFECTION. TESTED POSITIVE  ON 09/02/2021. PATIENT FULLY VACCINATED ON 04/22/2021.
Vaccine dose expired 10/13/2021, Vaccine was given to patient on 10/14/2021
Developed fever the evening of vaccines, then had a seizure. Seen in local ER. Blood culture, WBC done, f/u next 2 days in office.
Pt became very weak. Pt stated he felt as if he was going to pass out.  Pt assisted to lying postion.  Ammonia Inhalant adminstered.  Easily aroused  B/P 100/60 lying down.  ANRP called to assist and access.
Infant came in for her 2-month well child exam and received the following vaccinations: DTap-Hep B-IPV; Haemophilus b; pneumococcal 13-valent conjugate vaccines; and rotavirus vaccine (oral) vaccination.  Child was observed for 15 minutes and caregiver then took child to her vehicle. At that time, the caregiver returned the infant to the clinic and reported dark marks to her forehead along infant's forehead just below the hair line and one next to her lips. Child was observed her for an additional 30 -minutes and her spots started to go away. No other symptoms were noted. Infant then left the clinic with caregiver.
pt recvd vax 13DEC95 c/o abd cramps, n/v, fever on 18DEC95 x 2 wks;
Feeling very sickly; Vertigo; Diarrhea; Nausea; Vomitting; Headaches; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Feeling very sickly), VERTIGO (Vertigo), DIARRHOEA (Diarrhea), NAUSEA (Nausea) and VOMITING (Vomitting) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No reported medical history).    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jan-2021, the patient experienced MALAISE (Feeling very sickly), VERTIGO (Vertigo), DIARRHOEA (Diarrhea), NAUSEA (Nausea), VOMITING (Vomitting) and HEADACHE (Headaches). At the time of the report, MALAISE (Feeling very sickly), VERTIGO (Vertigo), DIARRHOEA (Diarrhea), NAUSEA (Nausea), VOMITING (Vomitting) and HEADACHE (Headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
12.5 hours after vaccine:  Body Aches, @ 18 hrs:  severe sleepiness and slight headache, @24 hours:  body aches, sleepiness, headache, chills, fever 101, scratchy throat with slight cough and hoarseness in throat, @31 hours all side effects lifted except scratchy throat and slight cough with hoarseness, @ 72 hours still have scratchy throat with slight cough and runny, itchy nose begins and continues for 5 more days, ending 1 week and 1 day after Moderna shot. Visited a local health care facility for COVID-19 test and diagnosis on day 5. Covid-19 test results were negative and diagnosis was reaction to 2nd Moderna shot. Advised to use Nasacort to control itchy and runny nose, which did help.
Document Type: US Thyroid Document Subject: US Thyroid   * Final Report *  Reason For Exam enlarged thyroid  Report EXAMINATION: Thyroid ultrasound   EXAM Date: 10/11/2022 08:44   HISTORY:  Enlarged thyroid.  COMPARISON: None available.  FINDINGS: Multiple grayscale and color Doppler ultrasound images of the thyroid gland are presented for interpretation.  The right thyroid lobe measures 4.6 cm sagittal by 1.3 cm AP by 1.5 cm transverse. The left thyroid lobe measures 4.1 cm sagittal by 1.2 cm AP by 1.3 cm transverse. The isthmus demonstrates normal thickness measuring approximately 0.2 cm. The right lobe contains a 1.0 cm well-circumscribed hypoechoic and slightly heterogeneous nodule that appears mildly hypervascular. No other nodules are identified in the right or left lobes.   IMPRESSION:  A 1.0 cm nodule in the right thyroid lobe is a TR4 lesion for which follow-up ultrasound is recommended at 1, 2, 3 and 5 years according to current ACR guidelines.   Dictated on: 10/11/2022 1:16 PM    Signature Line This examination and reported findings have been reviewed and confirmed by the undersigned.   Read By:  MD     Click VIEW IMAGE icon to Display Image This document has an image
This spontaneous report as received from a Registered Nurse refers to a currently 72 year female patient with hypertension, rheumatoid arthritis and hyperlipidemia. With no drug reactions or allergies. On an unknown date the patient was vaccinated with a dose of ZOSTAVAX (dose, route and lot # not reported). No concomitant medication were reported. On an unknown date the patient experienced bad rash on her arm where the vaccine was administered. No treatment was given for the adverse event. No laboratory test was performed. This nurse also reported another AE with ZOSTAVAX (MARRS # 1305USA005062). The outcome of bad rash on her arm was reported as not recovered/not resolved. Additional information has been requested.
Information has been received from a health professional concerning a 10 year old female patient with no known allergies who on 7/18/1996 was vaccinated SC with a dose of varicella virus vaccine live (lot 616998/1658B). On 5/19/2005 the patient was seen in the office and diagnosed with chickenpox. Treatment included calamine lotion and over the counter Ibuprofen Motrin. At the time of the report the patient was recovered. There was no product quality complaint involved. Additional information is not expected.
PATIENT HAD PRESENTED TO PHARMACY FOR A BOOSTRIX SHOT AND GOT THE COVID BIVALENT BOOSTER PFIZER INSTEAD. PATIENT DID NOT HAVE ANY IMMEDIATE  SIDE EFFECTS AT TIME OF GETTING THE VACCINE. SHE WAS ADMNISTERED THE CORRECT SHOT SHORTLY AFTER GETTING THE INCORRECT ONE.
Pt c/o "weakness" while seated in observation area. Was escorted to treatment area, able to ambulate. Vitals obtained ever 10m. Observed for 40 minutes. Given water & cereal bar. (Has H/O renal transplant, on immunosuppresants). Said he felt better but still a little weak. Advised to go home & rest & f/u with pcp.
Patient  is followed by our clinic for primary care, and received hepatitis A and B vaccinations on 1/22/2020 as part of his evaluation and treatment for chronic hepatitis C. After receiving the vaccines, Patient experienced several symptoms that he attributes to the vaccine that we are sharing with you for further monitoring and for consideration for the National Vaccine Injury Compensation Program. He describes his response as:   - weakness, dizziness, tiredness, blurred vision, double vision, and sensitivity to light - sore throat, muscle soreness, and sensation that his neck would fall off - multiple falls upon raising to standing - Mental Fogginess, disorientation, memory loss, ringing in the ears, loss of hearing in the right ear   His symptoms were persistent per his report through initiation of mavyret for his chronic hepatitis c, though the intensity of his symptoms was variable at times though he reports that it has persisted at least through today, March 5th.    Notably, his course was later complicated by development of Bell's Palsy on day 8 of mavyret therapy.
Patient tested positive following full COVID-19 vaccination.; Patient tested positive following full COVID-19 vaccination.; This is a spontaneous report from a non-contactable other HCP. A 52-year-old female patient received bnt162b2 (BNT162B2, Formulation; Solution for Injection), dose 1 via an unspecified route of administration on 11Mar2021 (Batch/Lot Number: EL3248) as DOSE 1, SINGLE, dose 2 via an unspecified route of administration on 30Mar2021 (Batch/Lot Number: EL3248) as DOSE 2, SINGLE (at the age of 52-year-old) for COVID-19 immunisation. It was unknown if patient was pregnant at time of vaccination. The patient medical history and concomitant medications were not reported. It was unknown if patient had COVID prior vaccination. It was unknown if the patient receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient tested positive following full COVID-19 vaccination on 25Aug2021 (COVID test positive). It was unknown if patient received treatment or not.  No follow-up attempts are possible. No further information is expected.
In November of 2022, shortly after receiving my second dose of Pfizer, I began to experience a lot of back pain. I went to the hospital and was diagnosed with kidney stones. On 01/25/2023, I began to experience back pain again. I went to the hospital again where they did a CT scan. They said that I may have already passed the stones. I was prescribed Cefpodoxime Pro. I finished taking that on 02/06/2023 and I feel 100 percent better at this point.
re-challenged w/HBOC on 16JUN94 w/in 20mins pt exp urticaria, poor perfusion, lethargy, hypotension, emesis x 2;given Epi & DPH inj & po pred resolved in 10 mins
patient had a headache after each dose of the Moderna Covid-19 vaccine; This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (patient had a headache after each dose of the Moderna Covid-19 vaccine) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Occipital neuralgia. Concurrent medical conditions included Hyperparathyroidism, Osteoporosis and Migraine. Concomitant products included ZOLMITRIPTAN (ZOMIG) and UBROGEPANT (UBRELVY) for Migraine, CLONAZEPAM (KLONOPIN), TRAZODONE, GABAPENTIN (NEURONTIN [GABAPENTIN]) and ERENUMAB (AIMOVIG [ERENUMAB]) for an unknown indication.   In 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced HEADACHE (patient had a headache after each dose of the Moderna Covid-19 vaccine). In 2021, HEADACHE (patient had a headache after each dose of the Moderna Covid-19 vaccine) had resolved.            The patient received the first dose of the Moderna Covid-19 vaccine early in 2021. Patient had a headache that lasted 1 to 2 days. After 28 days, the patient received the second dose of the Moderna Covid-19 vaccine. Patient had a headache for a week. Headache started 2 days after she received the vaccine. The patient received the first Moderna Monovalent booster dose about 6 months after the 2nd dose of primary series. Patient had a Headache that lasted for 10 days. The patient used Migraine medication which helped to take the edge off her Headache. Patient used Zomig and Ubrelvy.   This case was linked to MOD-2022-677452 (Patient Link).
Felt like Heroin withdrawal, fatigue, and irritated. Later rash and blisters near the joints, joint pain, worst of it on pelvis and hip. So far, only seen doctor for pain and was given the anti-shingles vax. Was recommended to take anti-histamine. Still waiting to see if it will clear up.
Joint pain in wrist and ankles lost strength in hands total body stiffness swelling in hands fingers.    Like arthritis over night.
migraines; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (migraines) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MIGRAINE (migraines). At the time of the report, MIGRAINE (migraines) outcome was unknown. Not Provided          This case was linked to MOD-2021-395778.
This spontaneous report was received from a medical assistant and refers to an unspecified number of patients of unknown age and gender. No information regarding the patients pertinent medical history, concomitant medication and drug reactions or allergies was reported. On unspecified dates starting on or after 19-FEB-2015, the patients were vaccinated with an unspecified number of improperly stored doses of (Oka/Merck) VARIVAX, lot # K016127, expiration date 23-SEP-2016 (strength, dose and route of administration were not provided). No adverse effects were reported. This is one of two reports received from the same source. Additional information has been requested.
No adverse event; A dose was then administered more than 24 hours after sitting at room temperature; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A dose was then administered more than 24 hours after sitting at room temperature) and NO ADVERSE EVENT (No adverse event) in a 10-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7645B) for COVID-19 prophylaxis.     The patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine.     On 13-Jul-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On 13-Jul-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (A dose was then administered more than 24 hours after sitting at room temperature). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (A dose was then administered more than 24 hours after sitting at room temperature) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (A dose was then administered more than 24 hours after sitting at room temperature).    No concomitant medication was reported. The vaccine was removed from fridge at on 12-JUL-2023. There were no reported symptoms. No treatment medication was reported.
Information has been received from a nurse and the mother concerning a 2 year old male who on 12/05/00 was vaccinated with MMR. On 10/09/01 and 10/18/01, the child had appointments at the pediatric department of a hospital for the Bayley's Scale of Infant Development. It was reported that the results were the child's motor skills were within normal limits, but his expressive language skills were at 12-18 month level. The child was noted to express speech delay and has been receiving speech therapy since 10/01. The child was recently referred to an ENT specialist fort a hearing test due to recurrent otitis media infections. On 05/15/02, the child had a hearing test and the results were reported  as normal. the child's expressive language disorder persisted. Upon internal review, the expressive language disorder was considered to be an other important medical event. Additional information has been requested. Additional information has been received from a physician who reported that he had no information on this matter. Additional information is not expected.
but most of the vaccine leaked out of her arm; but most of the vaccine leaked out of her arm; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team, Program ID.  A female patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), in 2023 as dose 1, single (Batch/Lot number: unknown), in arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION SITE EXTRAVASATION (non-serious), UNDERDOSE (non-serious) all with onset 2023, outcome "unknown" and all described as "but most of the vaccine leaked out of her arm".  Additional information: A pharmacist informed that a patient was vaccinated but most of the vaccine leaked out of her arm. They need guidance if they have to re-vaccinate the patient. Stated that a dose of COMIRNATY 2023-2024 formula Prefilled syringe was administered. Upon clarifying, it was mentioned that the immunizing pharmacist was able to administer the full dose.   The information on the batch/lot number for bnt162b2 omi xbb.1.5, bnt162b2 omi xbb.1.5  has been requested and will be submitted if and when received.  Follow-up (18Oct2023): This is a spontaneous follow-up report received from a contactable reporter(s) (Pharmacist), Program ID.  Updated information includes: Reporter information and patient initials. Previously reported information was amended: vaccine underdose was added as an event.  The information on the batch/lot number for bnt162b2 omi xbb.1.5, bnt162b2 omi xbb.1.5  has been requested and will be submitted if and when received.  Amendment: This follow-up report is being submitted to amend previous information: updated events 'Accidental exposure to product'+ 'Exposure via skin contact' to 'Vaccination site extravasation'.
Information has been received from a nurse concerning a female patient (age not reported) who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23. Concomitant medication was not reported. On 14-SEP-2007, the patient developed "serum toxicity" after she received PNEUMOVAX 23. She went to an emergency room on 14-SEP-2007 because of the symptom. The patient was treated with prednisone. The nurse was not sure if the patient was hospitalized. The patient was recovering from the serum toxicity. No product quality complaint was involved. Additional information has been requested.
Lymph edema started 3 days post injection. Started under arms. Day 4 it moved to left breast. Day 5 the swelling continued to left lower abdomen area and left labia. Skin is very tender to the touch in swollen areas
Information has been received from a physician concerning her son, who was vaccinated with a dose of varicella virus vaccine live and subsequently he experienced some lesions on the back of his neck and also a reactive lymph node. No other information is available regarding the adverse events or the pt's outcome. There was no product quality complaint reported. The pt sought unspecified medical attention. Additional information has been requested.
This spontaneous report was received from a physician via a company representative and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On an unknown date, the patient was vaccinated in error with a dose of RECOMBIVAX HB (also reported as "adult version of RECOMBIVAX" and "RECOMBIVAX HB INJ 40") injection, lot # M001579 (dose, route and site of administration and expiry date were not reported). No adverse reactions were reported. No product quality complaint was involved. Additional information has been requested.
answered yes, to experiencing side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (answered yes, to experiencing side effects) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (answered yes, to experiencing side effects). At the time of the report, VACCINATION COMPLICATION (answered yes, to experiencing side effects) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Headache, Myalgia, Arthralgia, NauseaVomiting Chills, no fever Narrative:  Other Relevant History:
EMPLOYEE STATED THAT HE IS EXPERIENCING CRAMPING AND PAIN ALL THE WAY UP THE RIGHT ARM. ALSO STATED THAT ARM IS SWOLLED AND VERY HARD TO THE TOUCH. ARM DID APPEAR TO BE SWOLLEN WITH SOME BRUISING AT THE INJECTION SITE AND ALSO SOME HARDNESS.
8 days after the injection site turned pink and raised and I experienced red itchy eyes and felt itchy all over.